Biomerica (NASDAQ:BMRA) Stock Price Crosses Below 200-Day Moving Average – Time to Sell?

Biomerica, Inc. (NASDAQ:BMRAGet Free Report)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.36 and traded as low as $0.27. Biomerica shares last traded at $0.33, with a volume of 377,159 shares changing hands.

Biomerica Stock Performance

The firm has a 50 day moving average price of $0.33 and a two-hundred day moving average price of $0.36. The company has a market capitalization of $5.47 million, a P/E ratio of -0.88 and a beta of -1.10.

Biomerica (NASDAQ:BMRAGet Free Report) last issued its quarterly earnings results on Tuesday, October 15th. The company reported ($0.08) earnings per share for the quarter. Biomerica had a negative net margin of 111.89% and a negative return on equity of 84.62%. The company had revenue of $1.81 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biomerica stock. Perritt Capital Management Inc purchased a new stake in Biomerica, Inc. (NASDAQ:BMRAFree Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 70,000 shares of the company’s stock, valued at approximately $31,000. Perritt Capital Management Inc owned 0.42% of Biomerica at the end of the most recent reporting period. Hedge funds and other institutional investors own 22.28% of the company’s stock.

About Biomerica

(Get Free Report)

Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.

Recommended Stories

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.